Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840409 · ClinicalTrials.gov registry record · Phase 2
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
A Phase 2 study of Low Grade Glioma, sponsored by The Hospital for Sick Children.
- Active
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 20
- Study locations
NCT02840409 is a Phase 2 study of Low Grade Glioma that is active but no longer recruiting, run by The Hospital for Sick Children. The registered enrollment target is 109 participants, roughly in line with the 109-participant average among 23 other Low Grade Glioma trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT02840409, a Phase 2 study of Low Grade Glioma, is active but no longer recruiting, sponsored by The Hospital for Sick Children.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68 weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks. Randomization will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Vinblastine
Study Locations (20)
Ontario
- McMaster Children's Hospital - Hamilton
- Children's Hospital - London Health Sciences Centre - London
- The Hospital for Sick Children - Toronto
Quebec
- Centre Hospitalier Universitaire Sainte-Justine - Montreal
- Montreal Children's Hospital - Montreal
- CHU du Quebec-Universite Laval - Québec
Alberta
- Alberta Children's Hospital - Calgary
- Stollery Children's Hospital - Edmonton
California
- Children's Hospital Los Angeles - Los Angeles
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02840409
The ClinicalTrials.gov registry entry for NCT02840409 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 109-participant average among 23 other Low Grade Glioma trials with a reported enrollment target. The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02840409 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Ontario, Quebec, Alberta.
Frequently Asked Questions
What is clinical trial NCT02840409 about?
NCT02840409 is a clinical study titled "Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)". This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants wil...
What is the current status of trial NCT02840409?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2016-08-01. Estimated completion is 2026-08.
What conditions does trial NCT02840409 study?
This clinical trial studies the following conditions: Low Grade Glioma.
What interventions are being tested in trial NCT02840409?
The interventions under investigation include: Bevacizumab (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT02840409?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02840409 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Georgia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Vaccine Trial for Low Grade Gliomas
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.